Akèy › Beta-talasemi
Etid klinik pou Beta-talasemi ap rekrite nan Etazini
15 etid pou Beta-talasemi ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
Pa eta
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 70 · Tout sèks · Mizajou Sep 28, 2026 · NCT03937817ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia
Ap rekriteFaz 1/2
Laj 18 a 40 · Tout sèks · Mizajou Sep 23, 2026 · NCT06364774Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
Ap rekriteFaz 1/2
Laj 4 a 65 · Tout sèks · Mizajou Sep 4, 2026 · NCT07599176T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
Ap rekriteFaz 1/2
Laj 5 a 40 · Tout sèks · Mizajou Aug 13, 2026 · NCT03653338Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Ap rekriteFaz 2
Laj 6 a 17 · Tout sèks · Mizajou Jul 10, 2026 · NCT04143724A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
Ap rekriteFaz 2
Laj 2 a 50 · Tout sèks · Mizajou Jun 3, 2026 · NCT05736419MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Ap rekriteFaz 2
Jiska laj 60 · Tout sèks · Mizajou Apr 6, 2026 · NCT05735717Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
Ap rekriteFaz 3
Laj 12 a 35 · Tout sèks · Mizajou Mar 23, 2026 · NCT05477563Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
Ap rekriteFaz 1
Laj 13 a 40 · Tout sèks · Mizajou Feb 3, 2026 · NCT06647979Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
Ap rekriteEtid obsèvasyon
2 Months – 60 Years · Tout sèks · Mizajou Jan 13, 2026 · NCT04528355Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jan 9, 2026 · NCT01245179Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
Ap rekriteFaz 2
2 Months – 55 Years · Tout sèks · Mizajou Dec 15, 2025 · NCT01962415AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Ap rekriteFaz 2
1 Day – 30 Years · Tout sèks · Mizajou Aug 8, 2025 · NCT04099966A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Feb 11, 2025 · NCT06271512Study of the Role of Genetic Modifiers in Hemoglobinopathies
Ap rekriteEtid obsèvasyon
Laj 2 ak plis · Tout sèks · Mizajou Mar 20, 2024 · NCT05799118Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.